ATE342722T1 - Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen - Google Patents

Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen

Info

Publication number
ATE342722T1
ATE342722T1 AT04731317T AT04731317T ATE342722T1 AT E342722 T1 ATE342722 T1 AT E342722T1 AT 04731317 T AT04731317 T AT 04731317T AT 04731317 T AT04731317 T AT 04731317T AT E342722 T1 ATE342722 T1 AT E342722T1
Authority
AT
Austria
Prior art keywords
strontium
cartilage
treatment
salts
water soluble
Prior art date
Application number
AT04731317T
Other languages
English (en)
Inventor
Christian Hansen
Henrik Nilsson
Jens E T Andersen
Stephan Christgau
Original Assignee
Osteologix As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33437111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE342722(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osteologix As filed Critical Osteologix As
Application granted granted Critical
Publication of ATE342722T1 publication Critical patent/ATE342722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/19—Pyruvic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
AT04731317T 2003-05-07 2004-05-06 Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen ATE342722T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300691 2003-05-07
DKPA200300932 2003-06-20
US52844203P 2003-12-09 2003-12-09
DKPA200301820 2003-12-09

Publications (1)

Publication Number Publication Date
ATE342722T1 true ATE342722T1 (de) 2006-11-15

Family

ID=33437111

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731317T ATE342722T1 (de) 2003-05-07 2004-05-06 Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen

Country Status (14)

Country Link
US (2) US7595342B2 (de)
EP (3) EP2266585B1 (de)
JP (3) JP4354984B2 (de)
AT (1) ATE342722T1 (de)
AU (1) AU2004237439B2 (de)
CA (1) CA2519189C (de)
CY (1) CY1105935T1 (de)
DE (1) DE602004002832T2 (de)
DK (1) DK1534305T3 (de)
ES (1) ES2275218T3 (de)
HK (1) HK1152494A1 (de)
PL (3) PL1745791T3 (de)
PT (1) PT1534305E (de)
WO (1) WO2004098619A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1534305T3 (da) 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
SI2266584T1 (sl) 2003-05-07 2012-12-31 Osteologix A/S, Symbion Sestavek s stroncijem in vitaminom D za profilakso in/ali zdravljenje patologij hrustanca in/ali kosti
JP5049589B2 (ja) * 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
CA2557324C (en) 2004-02-26 2012-10-16 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
DK1768748T4 (da) 2004-06-25 2019-06-11 Mokwalo Spf S A Sammensætninger omfattende strontium og vitamin D og anvendelser deraf
ES2582942T3 (es) 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
PL372183A1 (pl) * 2005-01-11 2006-07-24 Sgp & Sons Ab Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
DE102005012971A1 (de) * 2005-03-21 2006-09-28 Merckle Gmbh Polymorphe Form von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure
JP2009500358A (ja) * 2005-07-06 2009-01-08 オステオロジックス エイ／エス ストロンチウムの有機塩を製造するための高収率合成法
EP1928855A2 (de) 2005-08-19 2008-06-11 Glenmark Pharmaceuticals Limited Verfahren zur darstellung von strontiumranelat
RU2454999C2 (ru) * 2005-11-15 2012-07-10 Энтресс Аб Лекарственное средство, применяющееся при поражениях хряща
CA2651827C (en) 2006-05-26 2013-11-26 Baxter International Inc. Injectable fibrin composition for bone augmentation
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CA2686820C (en) * 2007-04-23 2016-06-28 Baxter International Inc. Fibrin compositions containing strontium compounds
US8372992B2 (en) * 2007-06-01 2013-02-12 Nutraceutical Corporation Strontium (M) ascorbate, compositions containing same, method for making same and method of using same
EP2014319A1 (de) 2007-07-09 2009-01-14 Astra Tech AB Knochengewebeimplantat mit Strontiumionen
EP2014259A1 (de) 2007-07-09 2009-01-14 Astra Tech AB Knochengewebeimplantat mit Lithiumionen
US8378126B2 (en) * 2007-08-01 2013-02-19 Nutraceutical Corporation Strontium (M) ascorbate, compositions containing same, method for making same and method of using same
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2416756A2 (de) 2009-04-10 2012-02-15 Mahmut Bilgic Stabile pharmazeutische zusammensetzungen mit hoher bioverfügbarkeit
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US9724355B2 (en) 2010-09-16 2017-08-08 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
WO2013013003A1 (en) * 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
US10232090B2 (en) 2013-08-23 2019-03-19 Southwest Research Institute Electrophoretically deposited strontium fluoride nanoparticle/polymer coatings for medical implants
US9820968B2 (en) * 2013-09-24 2017-11-21 Council Of Scientific And Industrial Research Anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells
RU2547787C1 (ru) * 2013-12-16 2015-04-10 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт травматологии и ортопедии имени В.Д. Чаклина" Министерства здравоохранения Российской Федерации Способ оптимизации состояния суставного хряща при экспериментальном иммобилизационном остеопорозе
WO2015123229A1 (en) * 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms
WO2016130686A1 (en) 2015-02-11 2016-08-18 Cosmederm Bioscience, Inc. Stable high concentration strontium compounds and formulations for topical application
WO2016141219A1 (en) 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
EP3284462B1 (de) 2016-08-17 2022-08-03 Galleon Labs LLC Strontiumhaltige komplexe zur behandlung von schmerzen, juckreiz und entzündungen
US10463636B2 (en) * 2016-09-30 2019-11-05 Deanna J. Nelson Pharmaceutical quality strontium L-lactate
WO2019118952A1 (en) * 2017-12-15 2019-06-20 Clarke Lewis Kilman Veterinary supplement for effecting bone and cartilage
US11530232B2 (en) * 2019-11-14 2022-12-20 Alliance For Sustainable Energy, Llc Reversibly soluble bases for lignin oxidative depolymerization
RU2730133C1 (ru) * 2020-05-04 2020-08-18 Евгений Владимирович Плотников Геропротекторное средство
CN114716310A (zh) * 2022-06-08 2022-07-08 中国科学院过程工程研究所 一种柠檬酸锶及其制备方法

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB241266A (en) 1924-07-14 1925-10-14 Knoll & Co Chem Fab Improvements in the manufacture of double compounds of dimethylxanthines, earth alkali and salicylic acid
NL77097C (de) 1952-04-29
GB990957A (en) 1964-02-24 1965-05-05 Stafford Miller Ltd Strontium ion-containing toothpaste
SE340807B (de) * 1966-05-06 1971-12-06 Astra Ab
US4056567A (en) * 1976-03-08 1977-11-01 Lever Brothers Company Chemical processes for preparing citric acid
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
DE3735264C1 (de) * 1987-10-17 1988-08-25 Degussa Verfahren zur Herstellung von Erdalkalimetallsalzen der L-2-Pyrrolidon-5-carbonsaeure
US5160737A (en) 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
FR2633619B1 (fr) * 1988-06-29 1991-02-08 Adir Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
DE69008555T3 (de) 1989-01-31 1998-09-17 Yissum Res Dev Co Dentalzusammensetzung für überempfindliche Zähne.
GB8906914D0 (en) 1989-03-28 1989-05-10 Beecham Group Plc Novel compositions
FR2651497B1 (fr) 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2658816A1 (fr) * 1990-02-27 1991-08-30 Adir Nouveaux sels de metaux alcalinoterreux d'oxa-polyacides leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2665896A1 (fr) 1990-08-16 1992-02-21 Rhone Poulenc Chimie Carboxylates metalliques, leur preparation et compositions supraconductrices obtenues a partir de ceux-ci.
ATE160345T1 (de) 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DK0731795T3 (da) * 1993-11-30 2000-05-15 Searle & Co Substituerede pyrazolylbenzensulfonamider til behandling af inflammation
US5401765A (en) 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5475021A (en) * 1993-12-03 1995-12-12 Vanderbilt University Compounds and compositions for inhibition of cyclooxygenase activity
ATE179168T1 (de) 1994-02-10 1999-05-15 Searle & Co Substituierte spiroverbindungen zur behandlung von entzündungen
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
AU2424895A (en) 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
RU2200158C2 (ru) * 1995-02-13 2003-03-10 Джи.Ди.Сирл энд Ко. Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
SK133297A3 (en) 1995-04-04 1998-07-08 Glaxo Group Ltd Imidazo[1,2-a]pyridine derivatives, pharmaceutical composition containing same and their use
EP0737471A3 (de) * 1995-04-10 2000-12-06 L'oreal Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung
EP0825989A1 (de) 1995-05-19 1998-03-04 G.D. Searle & Co. Substituierte oxazole zur behandlung von entzündung
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
ES2150679T3 (es) 1995-07-21 2000-12-01 Nycomed Austria Gmbh Derivados de bencenosulfonamidas como inhibidores de la enzima ciclooxigenasa ii.
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5906809A (en) * 1995-10-19 1999-05-25 University Of Maryland, Baltimore One-step method and preparation for reducing dentinal hypersensitivity
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
EP0900083B1 (de) 1996-01-11 2003-08-20 Smithkline Beecham Corporation Neue substituierte imidazolverbindungen
AU730642B2 (en) 1996-01-26 2001-03-08 G.D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
WO1997029776A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
ES2125161B1 (es) 1996-03-21 1999-11-16 Grupo Farmaceutico Almirall S Nuevos derivados de 2-(3h)-oxazolona.
FR2747123B1 (fr) 1996-04-04 1998-06-26 Union Pharma Scient Appl Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
CN1098256C (zh) 1996-04-12 2003-01-08 G·D·瑟尔公司 作为cox－2抑制剂前药的取代的苯磺酰胺衍生物
US5756531A (en) 1996-04-30 1998-05-26 Abbott Laboratories Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5696431A (en) * 1996-05-03 1997-12-09 Philips Electronics North America Corporation Inverter driving scheme for capacitive mode protection
AU3122597A (en) 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
NZ332670A (en) 1996-05-17 2000-07-28 Merck & Co Inc Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases comprising 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone
HRP970289A2 (en) 1996-05-31 1998-04-30 Merck & Co Inc Process for preparing phenyl heterocycles useful as cox-2 inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5750558A (en) * 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
US5945538A (en) * 1996-06-28 1999-08-31 American Cyanamid Company Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
NZ333230A (en) 1996-07-18 2000-08-25 Merck Frosst Canada Inc Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
BR9710597A (pt) 1996-07-26 1999-08-17 American Home Prod P¡rano¡ndol e carbazol inib¡dores de cox-2
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
CA2264104A1 (en) 1996-08-14 1998-02-19 G.D. Searle & Co. Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
HUP9904696A2 (hu) 1996-11-12 2000-05-28 American Home Products Corporation COX-2 Enzim indén-típusú inhibitorai
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
DK0946507T3 (da) * 1996-12-10 2004-01-26 Searle & Co Substituerede pyrrolylforbindelser til behandling af inflammation
PA8444901A1 (es) 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
ATA16597A (de) 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
US5792446A (en) 1997-02-18 1998-08-11 Collagenex Pharmaceuticals, Inc. Delivery system for administering dentin-hypersensitivity-ameliorating compositions
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
DE69816047T2 (de) 1997-03-14 2004-04-22 Merck Frosst Canada & Co, Kirkland (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
WO1998041511A1 (en) 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
AU6518598A (en) 1997-03-28 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6
WO1998043966A1 (en) 1997-04-02 1998-10-08 Merck Frosst Canada & Co. Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
DE69810938T2 (de) 1997-04-11 2003-11-06 Grelan Pharmaceutical Co Pyrazolderivate und sie enthaltende cox-inhibitoren
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
CN1253502A (zh) 1997-04-18 2000-05-17 G·D·西尔公司 利用环氧化酶－2的抑制物预防心血管疾病的方法
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
WO1998050075A1 (en) 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
WO1999010331A1 (en) 1997-08-22 1999-03-04 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
WO1999010332A1 (en) 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SK283922B6 (sk) 1997-09-05 2004-05-04 Glaxo Group Limited 2,3-Diarylpyrazolo[1,5-b]pyridazínové zlúčeniny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
ES2226167T3 (es) 1997-09-12 2005-03-16 MERCK FROSST CANADA & CO. Piridinas 2,3,5-sustituidas como inhibidores de ciclooxigenasa 2.
ES2239402T3 (es) 1997-09-12 2005-09-16 MERCK FROSST CANADA & CO. 2-aminopiridinas como inhibidores de ciclooxigenasa-2.
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AUPO990097A0 (en) 1997-10-21 1997-11-13 University Of Sydney, The Medicinal uses of phenylalkanols and derivatives (gingerol analogues)
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2770131A1 (fr) 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
EP1028951A1 (de) 1997-10-30 2000-08-23 Merck Frosst Canada Inc. Diaryl-5-alkyl-5-methyl-2(5h)-furanone als selektive cyclooxygenase-2-inhibitoren
AU758566B2 (en) 1997-10-31 2003-03-27 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
CA2316953A1 (en) 1997-12-26 1999-07-08 Nissin Food Products Co., Ltd. 5-arylpyrrole derivatives
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
AU1527099A (en) 1998-01-09 1999-07-26 Enamelon, Inc. Solid products and methods for the remineralization and prevention of demineralization of teeth
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
AU754064B2 (en) 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
GB9810920D0 (en) 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
AU3953899A (en) 1998-05-27 1999-12-13 Nippon Shinyaku Co. Ltd. Cyclooxygenase-2 inhibitors
ES2137138B1 (es) 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
TNSN99111A1 (fr) 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
SE9802333D0 (sv) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
JP2000016935A (ja) 1998-07-01 2000-01-18 Dai Ichi Seiyaku Co Ltd シクロオキシゲナーゼ阻害剤
GB9814316D0 (en) 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
ES2140354B1 (es) 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
DE19837522A1 (de) * 1998-08-19 2000-02-24 Clariant Gmbh Verwendung von Metall-Carboxylaten und -Sulfonaten als Ladungssteuermittel
KR100295206B1 (ko) 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
SK286806B6 (sk) 1998-10-27 2009-05-07 Abbott Laboratories Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
JP3420751B2 (ja) 1998-11-03 2003-06-30 グラクソ グループ リミテッド 選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体
AU1408699A (en) 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
AU1398899A (en) 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
JP2002533387A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法
US6232497B1 (en) * 1998-12-23 2001-05-15 Skw Trostberg Aktiengesellschaft Method for producing alkali metal and alkaline earth metal pyruvates
ATE328593T1 (de) 1999-01-07 2006-06-15 Univ Vanderbilt Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren
AU3596500A (en) 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
JP2002538176A (ja) 1999-03-01 2002-11-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トラマドール物質および選択的ｃｏｘ−２阻害薬を含んで成る組成物
DE60023119T2 (de) 1999-03-10 2006-07-20 G.D. Searle Llc Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
US6211210B1 (en) 1999-05-07 2001-04-03 Merck Frosst Canada & Co. Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US20020018748A1 (en) * 2000-04-03 2002-02-14 Stanley Satz Method for targeted radiotherapy, pain palliation and imaging of osteoblastic skeletal tumors and composition therefore
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
SI1365769T1 (sl) 2001-02-06 2011-06-30 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Zdravilo za zdravljenje osteonekroze za oskrbo pacientov pri tveganju razvoja osteonekroze
US6365152B1 (en) * 2001-03-15 2002-04-02 Bovine Health Products, Inc. Scours treatment and method of making same
WO2003003664A1 (en) 2001-06-27 2003-01-09 Hyglo Ab System and method for address and key distribution in virtual networks
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
SE0201713D0 (sv) 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
WO2003075741A2 (en) 2002-03-04 2003-09-18 Medimmune, Inc. METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
DE10225420A1 (de) 2002-06-07 2003-12-24 Sanatis Gmbh Strontium-Apatit-Zement-Zubereitungen, die daraus gebildeten Zemente und die Verwendung davon
US7273523B2 (en) * 2002-06-07 2007-09-25 Kyphon Inc. Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
FR2844797B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr) * 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
US7056634B2 (en) * 2002-10-10 2006-06-06 Canon Kabushiki Kaisha Yellow toner
FR2846558B1 (fr) 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
EP1605955B1 (de) 2003-03-27 2015-08-19 SantoSolve AS Entzündungshemmende Zusammensetzung auf der Basis von Strontiumverbindungen
JP5049589B2 (ja) * 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
SI2266584T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S, Symbion Sestavek s stroncijem in vitaminom D za profilakso in/ali zdravljenje patologij hrustanca in/ali kosti
DK1534305T3 (da) * 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
FR2862224A1 (fr) 2003-11-14 2005-05-20 Medesis Pharma Sa Complexes a base de strontium, pharmaceutiques et produits dietetiques
CA2557324C (en) * 2004-02-26 2012-10-16 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US7589235B2 (en) * 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
CA2570503A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S A method of improving the medical treatment of pain
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
WO2005123098A2 (en) 2004-06-17 2005-12-29 Osteologix A/S Preventing gastrointestinal side-effects with strontium salts
EP1855654A1 (de) 2005-02-28 2007-11-21 Osteologix A/S Tabletten mit hoher strontiumladung
JP2009500358A (ja) * 2005-07-06 2009-01-08 オステオロジックス エイ／エス ストロンチウムの有機塩を製造するための高収率合成法

Also Published As

Publication number Publication date
AU2004237439A1 (en) 2004-11-18
DK1534305T3 (da) 2007-02-05
JP2006525243A (ja) 2006-11-09
PL1745791T3 (pl) 2013-11-29
PT1534305E (pt) 2007-02-28
EP1534305B9 (de) 2007-03-07
DE602004002832D1 (de) 2006-11-30
EP1745791A2 (de) 2007-01-24
EP1534305A2 (de) 2005-06-01
US20060122274A1 (en) 2006-06-08
EP1534305B1 (de) 2006-10-18
EP1745791B1 (de) 2013-06-26
JP2012167100A (ja) 2012-09-06
CY1105935T1 (el) 2011-04-06
CA2519189A1 (en) 2004-11-18
EP1745791A3 (de) 2011-03-30
JP5244995B2 (ja) 2013-07-24
US20100048697A1 (en) 2010-02-25
WO2004098619A3 (en) 2005-03-10
ES2275218T3 (es) 2007-06-01
JP4354984B2 (ja) 2009-10-28
DE602004002832T2 (de) 2007-06-06
EP2266585B1 (de) 2013-06-26
HK1152494A1 (en) 2012-03-02
US7595342B2 (en) 2009-09-29
PL1534305T3 (pl) 2007-03-30
US8541471B2 (en) 2013-09-24
JP5036765B2 (ja) 2012-09-26
EP2266585A2 (de) 2010-12-29
AU2004237439B2 (en) 2009-09-10
JP2009263381A (ja) 2009-11-12
CA2519189C (en) 2012-07-17
WO2004098619A2 (en) 2004-11-18
EP2266585A3 (de) 2011-05-04
PL2266585T3 (pl) 2013-10-31

Similar Documents

Publication Publication Date Title
ATE342722T1 (de) Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
ATE421322T1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
DE602004020263D1 (de) Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
EP2308833A3 (de) Zyklische Proteintyrosinkinaseinhibitoren
EA200601095A1 (ru) Замещённые гетероароилом фенилаланинамиды
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE422884T1 (de) Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
ATE457981T1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
NO20055694D0 (no) Fremgangsmate for fremstilling av (4-hydroksy-6-oksotetrahydropyran-2-yl)acetonitril og derivater derav
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE59909607D1 (de) Tan-1057 derivate
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
ATE253368T1 (de) Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen
MXPA02010822A (es) Metodo para incrementar la productividad de una planta usando acido glutamico y acido glicolico.
DE60310609D1 (de) Verfahren zur herstellung von 2-aminomethylpyridin-derivaten
DE602004023102D1 (de) Verfahren zur herstellung kristalliner formen von orlistat
DE60013326D1 (de) Verbindungen und verfahren zur behandlung von schmerz
CY1114355T1 (el) Υδατοδιαλυτα αλατα στροντιου για χρηση στην θεραπεια των παθησεων του χονδρου ή/και των οστων
BRPI0417179A (pt) gentisato de amlodipina, método de preparar o mesmo e composição farmacêutica para tratamento de doenças cardiovasculares
ATE451367T1 (de) Verfahren zur herstellung von ziprasidon
BR0314526A (pt) Composições farmacêuticas para o tratamento do mal de parkinson
ATE431148T1 (de) Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534305

Country of ref document: EP